

## Part VI – Summary of the risk management plan by product

### Summary of risk management plan for <Product name> 50 micrograms/0.5 mg per g gel

This is a summary of the risk management plan (RMP) for <Product name> 50 micrograms/0.5 mg per g gel. The RMP details important risks of <Product name>, how these risks can be minimised, and how more information will be obtained about <Product name> risks and uncertainties (missing information).

<Product name> 50 micrograms/0.5 mg per g gel summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how calcipotriol betamethasone combination should be used.

#### ***I. The medicine and what it is used for***

<Product name> 50 micrograms/0.5 mg per g gel will be used for topical treatment of scalp psoriasis in adults. Topical treatment of mild to moderate “non-scalp” plaque psoriasis vulgaris in adults.

The product contains calcipotriol (as monohydrate) and betamethasone (as dipropionate) as the active substances and it is used topically.

#### ***II. Risks associated with the medicine and activities to minimise or further characterise the risks***

Important risks of <Product name>, together with measures to minimise such risks and the proposed studies for learning more about <Product name> risks, are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine’s packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine’s legal status — the way a medicine is supplied to the patient (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute *routine risk minimisation* measures.

In addition to these measures, information about adverse reactions is collected continuously and regularly analysed so that immediate action can be taken as necessary. These measures constitute *routine pharmacovigilance activities*.

If important information that may affect the safe use of <Product name> is not yet available, it is listed under ‘missing information’ below.

#### ***II.A List of important risks and missing information***

Important risks of <Product name> are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient

proof of a link with the use of <Product name>. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine).

The list of safety concerns published by the CMDh was reviewed (CMDh\_330\_2015\_Rev23\_2020\_02) and the most recent risks for calcipotriol/betamethasone combination are listed.

<b>Important identified risks</b>	Skin atrophy
	HPA axis suppression
	Rebound phenomenon
	Secondary infections
	Hypercalcaemia
<b>Important potential risks</b>	Potential enhancement of UV radiation induced skin cancer
<b>Missing information</b>	Safety and efficacy in children below 18 years
	Safety and efficacy in patients with severe renal insufficiency or severe hepatic disorders

### ***II.B Summary of important risks***

The safety information in the proposed Product Information is aligned to the reference medicinal product.

### ***II.C Post-authorisation development plan***

#### **II.C.1 Studies which are conditions of the marketing authorisation**

There are no studies which are conditions of the marketing authorisation or specific obligation of <Product name>.

#### **II.C.2 Other studies in post-authorisation development plan**

There are no studies required for <Product name>.